Risk factors for immune-related adverse events: what have we learned and what lies ahead?

Abstract Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaoyan Liu, Yuequan Shi, Dongming Zhang, Qing Zhou, Jia Liu, Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Mengzhao Wang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Immune checkpoint inhibitor Immune-related adverse events Mechanism Risk factor Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/3287374572c741c0b18e6863d74ba14b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3287374572c741c0b18e6863d74ba14b
record_format	dspace
spelling	oai:doaj.org-article:3287374572c741c0b18e6863d74ba14b2021-11-07T12:12:46ZRisk factors for immune-related adverse events: what have we learned and what lies ahead?10.1186/s40364-021-00314-82050-7771https://doaj.org/article/3287374572c741c0b18e6863d74ba14b2021-11-01T00:00:00Zhttps://doi.org/10.1186/s40364-021-00314-8https://doaj.org/toc/2050-7771Abstract Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for inducing autoimmune toxic effects, collectively termed immune-related adverse events (irAEs). These autoimmune adverse effects are often difficult to predict, possibly permanent, and occasionally fatal. Hence, the identification of risk factors for irAEs is urgently needed to allow for prompt therapeutic intervention. This review discusses the potential mechanisms through which irAEs arise and summarizes the existing evidence regarding risk factors associated with the occurrence of irAEs. In particular, we examined available data regarding the effect of a series of clinicopathological and demographic factors on the risk of irAEs.Xiaoyan LiuYuequan ShiDongming ZhangQing ZhouJia LiuMinjiang ChenYan XuJing ZhaoWei ZhongMengzhao WangBMCarticleImmune checkpoint inhibitorImmune-related adverse eventsMechanismRisk factorTherapeutics. PharmacologyRM1-950ENBiomarker Research, Vol 9, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immune checkpoint inhibitor Immune-related adverse events Mechanism Risk factor Therapeutics. Pharmacology RM1-950
spellingShingle	Immune checkpoint inhibitor Immune-related adverse events Mechanism Risk factor Therapeutics. Pharmacology RM1-950 Xiaoyan Liu Yuequan Shi Dongming Zhang Qing Zhou Jia Liu Minjiang Chen Yan Xu Jing Zhao Wei Zhong Mengzhao Wang Risk factors for immune-related adverse events: what have we learned and what lies ahead?
description	Abstract Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for inducing autoimmune toxic effects, collectively termed immune-related adverse events (irAEs). These autoimmune adverse effects are often difficult to predict, possibly permanent, and occasionally fatal. Hence, the identification of risk factors for irAEs is urgently needed to allow for prompt therapeutic intervention. This review discusses the potential mechanisms through which irAEs arise and summarizes the existing evidence regarding risk factors associated with the occurrence of irAEs. In particular, we examined available data regarding the effect of a series of clinicopathological and demographic factors on the risk of irAEs.
format	article
author	Xiaoyan Liu Yuequan Shi Dongming Zhang Qing Zhou Jia Liu Minjiang Chen Yan Xu Jing Zhao Wei Zhong Mengzhao Wang
author_facet	Xiaoyan Liu Yuequan Shi Dongming Zhang Qing Zhou Jia Liu Minjiang Chen Yan Xu Jing Zhao Wei Zhong Mengzhao Wang
author_sort	Xiaoyan Liu
title	Risk factors for immune-related adverse events: what have we learned and what lies ahead?
title_short	Risk factors for immune-related adverse events: what have we learned and what lies ahead?
title_full	Risk factors for immune-related adverse events: what have we learned and what lies ahead?
title_fullStr	Risk factors for immune-related adverse events: what have we learned and what lies ahead?
title_full_unstemmed	Risk factors for immune-related adverse events: what have we learned and what lies ahead?
title_sort	risk factors for immune-related adverse events: what have we learned and what lies ahead?
publisher	BMC
publishDate	2021
url	https://doaj.org/article/3287374572c741c0b18e6863d74ba14b
work_keys_str_mv	AT xiaoyanliu riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT yuequanshi riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT dongmingzhang riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT qingzhou riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT jialiu riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT minjiangchen riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT yanxu riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT jingzhao riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT weizhong riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead AT mengzhaowang riskfactorsforimmunerelatedadverseeventswhathavewelearnedandwhatliesahead
_version_	1718443477774106624

Risk factors for immune-related adverse events: what have we learned and what lies ahead?

Ejemplares similares